GRACE THERAPEUTICS INC(GRCE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GRCE GRACE THERAPEUTICS INC

交易中 08-25 12:16:29 EDT

2.21

+0.03

+1.38%

最高2.22	最低2.18	成交量5.89万
今开2.21	昨收2.18	日振幅1.83%
总市值4,649万	流通市值3,429万	总股本2,104万
成交额12.97万	换手率0.38%	流通股本1,551万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GRCE","market":"US","secType":"STK","nameCN":"GRACE THERAPEUTICS INC","latestPrice":2.21,"timestamp":1787674560822,"preClose":2.18,"halted":0,"volume":58940,"delay":0,"changeRate":0.013761467889908166,"floatShares":15513699,"shares":21035900,"eps":-1.200273,"marketStatus":"交易中","change":0.03,"latestTime":"08-25 12:16:29 EDT","open":2.205,"high":2.22,"low":2.18,"amount":129670.982364,"amplitude":0.018349,"askPrice":2.21,"askSize":2746,"bidPrice":2.19,"bidSize":448,"shortable":3,"etf":0,"ttmEps":-1.200273,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":2.18,"preHourTrading":{"tag":"盘前","latestPrice":2.18,"preClose":2.18,"latestTime":"09:01 EDT","volume":20,"amount":43.6,"timestamp":1787662869883,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.18,"preClose":2.18,"latestTime":"19:30 EDT","volume":139,"amount":299.21,"timestamp":1787614206347,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.431022,"impliedVol":0.9333,"impliedVolPercentile":0.4564},"requestUrl":"/m/hq/s/GRCE","defaultTab":"news","newsList":[{"id":"1119894941","title":"Grace Therapeutics提交SEC文件：现有股东可转售最多4,761,904股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1119894941","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119894941?lang=zh_cn&edition=full","pubTime":"2026-08-25 04:08","pubTimestamp":1787602093,"startTime":"0","endTime":"0","summary":"Grace Therapeutics公司最新披露的SEC文件显示，公司现有股东被允许转售最多4,761,904股普通股。根据该文件内容，此次可转售的股份数量已明确锁定在近476万股的水平。这一安排意味着持有这些股份的现有股东将有机会在市场上进行交易变现。对于市场而言，这类股东转售行为可能会对股票短期供给产生一定影响，但具体影响程度还需结合市场整体环境来评估。Grace Therapeutics此次提交的SEC文件为投资者提供了重要的股权变动信息，值得市场参与者密切关注后续动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113784980","title":"Grace Therapeutics 宣布收到美国食品药品监督管理局A类会议纪要","url":"https://stock-news.laohu8.com/highlight/detail?id=1113784980","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113784980?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:04","pubTimestamp":1785236686,"startTime":"0","endTime":"0","summary":"Grace Therapeutics 宣布已收到美国食品药品监督管理局（FDA）的A类会议纪要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146744826","title":"Grace Therapeutics公司GTX-104药物遭监管点名 涉及浸出物数据、毒理学评估及生产缺陷","url":"https://stock-news.laohu8.com/highlight/detail?id=1146744826","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146744826?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:17","pubTimestamp":1776964647,"startTime":"0","endTime":"0","summary":"美国生物制药公司Grace Therapeutics Inc.近期披露，其核心候选药物GTX-104遭到监管机构审查，涉及多项关键问题。根据公开信息，监管指出的项目包括药物浸出物研究数据、毒理学安全评估报告以及生产环节存在的缺陷。毒理学评估则用于判断药物潜在毒性风险，这两项数据的完整性对药物获批至关重要。此外，生产环节的缺陷可能影响药品质量的一致性与稳定性。此次监管关注点集中在该公司的主打产品GTX-104上，这款药物正处于关键开发阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165355983","title":"Grace Therapeutics宣布STRIVE-ON三期试验结果摘要获选将在2026年美国神经病学学会年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1165355983","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165355983?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:08","pubTimestamp":1776168512,"startTime":"0","endTime":"0","summary":"Grace Therapeutics（股票代码：GRCE）近日宣布，其针对STRIVE-ON三期临床试验结果的研究摘要已获接受，将于2026年美国神经病学学会（AAN）年会上进行正式报告。\n该摘要重点突出了STRIVE-ON试验的关键数据，这项三期临床研究旨在评估公司某在研疗法的有效性与安全性。此次获选在权威学术会议上展示，标志着该临床试验结果获得了神经病学领域的专业认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108073478","title":"Grace Therapeutics第三季度每股收益为-0.36美元, 低于预估的-0.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108073478","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108073478?lang=zh_cn&edition=full","pubTime":"2025-02-13 21:09","pubTimestamp":1739452160,"startTime":"0","endTime":"0","summary":"Grace Therapeutics第三季度每股收益为-0.36美元, 低于预估的-0.34美元以上内容来自Benzinga Earnings专栏，原文如下：Grace $Therapeutics(LENZ)$ Q3 EPS $(0.36) Vs $(0.34) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2485982672","title":"Grace Therapeutics, Inc.2024财年第三财季实现净利润-3.43百万美元，同比减少4.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485982672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2485982672?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:00","pubTimestamp":1732291227,"startTime":"0","endTime":"0","summary":"11月23日，Grace Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-3.43百万美元，同比减少4.89%；其中营业收入为0.00美元，每股基本收益为-0.30美元。从资产负债表来看，Grace Therapeutics, Inc.总负债9.22百万美元，其中短期债务0.00美元，资产负债比为7.09，流动比率为6.02。机构评级：截至2024年11月23日，当前有3家机构对Grace Therapeutics, Inc.目标价做出预测，其中目标均价为10.83美元，其中最低目标价为8.00美元，最高目标价为12.50美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000055a24e4853&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000055a24e4853&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GRCE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gracetx.com","stockEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":-0.0644},{"period":"3month","weight":-0.0763},{"period":"6month","weight":-0.4644},{"period":"1year","weight":-0.3292},{"period":"ytd","weight":-0.3699}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Grace Therapeutics, Inc.成立于2002年2月1日。他们专注于开发和商业化用于罕见和孤儿疾病的产品，这些产品有可能通过使用他们的新型药物递送技术来改善临床结果。他们寻求将新的专有配方应用于已获批准和上市的药物化合物，以实现增强疗效、更快起效、减少副作用、更方便的药物递送和提高患者依从性。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.036577},{"month":2,"riseRate":0.357143,"avgChangeRate":-0.018558},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.04693},{"month":4,"riseRate":0.214286,"avgChangeRate":-0.071072},{"month":5,"riseRate":0.642857,"avgChangeRate":0.009324},{"month":6,"riseRate":0.5,"avgChangeRate":0.001941},{"month":7,"riseRate":0.428571,"avgChangeRate":0.131746},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.142455},{"month":9,"riseRate":0.461538,"avgChangeRate":0.081587},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.11872},{"month":11,"riseRate":0.538462,"avgChangeRate":-0.024598},{"month":12,"riseRate":0.769231,"avgChangeRate":0.071767}],"exchange":"NASDAQ","name":"GRACE THERAPEUTICS INC","nameEN":"GRACE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRACE THERAPEUTICS INC(GRCE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供GRACE THERAPEUTICS INC(GRCE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"GRACE THERAPEUTICS INC,GRCE,GRACE THERAPEUTICS INC股票,GRACE THERAPEUTICS INC股票老虎,GRACE THERAPEUTICS INC股票老虎国际,GRACE THERAPEUTICS INC行情,GRACE THERAPEUTICS INC股票行情,GRACE THERAPEUTICS INC股价,GRACE THERAPEUTICS INC股市,GRACE THERAPEUTICS INC股票价格,GRACE THERAPEUTICS INC股票交易,GRACE THERAPEUTICS INC股票购买,GRACE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRACE THERAPEUTICS INC(GRCE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供GRACE THERAPEUTICS INC(GRCE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}